Creating a new paradigm for this disease through the development of new personalised cancer therapeutic approaches.

By leveraging new knowledge and understanding brain metastasis’ processes and properties, we aim to challenge the three pillars underlying the poor prognosis of this disease: high lethality, therapeutic resistance and impact in neurocognition and quality of life, for a more rapid development of new diagnostics, treatments, biomarkers, and better approaches in the clinical practice.

Renacer

The Spanish National Network on Brain Metastases (RENACER) consists of a cooperative framework of national reference hospitals, research laboratories and a biobank, which collaborate with each other with the aim of creating a unique collection of human samples and data to promote research on brain metastases, with a view to improving both their diagnosis and treatment.

Through the different complementary and cross-cutting perspectives offered by the RENACER framework, we will advance the development of new, more precise and effective approaches, therapies and personalised treatments. Without RENACER, this work would be almost impossible.

Members & coordinators

RENACER, established at national level, with international vision, is formed by health institutions, basic/translational laboratories and a biobank, which work closely with multidisciplinary groups with diverse backgrounds and expertise, to address the underlying pillars of brain metastasis and its poor prognosis. Learn more about our team on our website.

Results & Achievements

This project aims to disrupt the systemic strategy applied for brain metastases treatment, by leveraging new knowledge and understanding of this disease’s processes and vulnerabilities. Visit our website to learn more about our achievements and ongoing research.

Projects

RENACER, as a national and international reference for researchers and clinicians interested in brain metastases, acts as a critical mass for the organisation of joint research projects, in an ongoing effort to benefit patients. Several initiatives in this regard have been created.

Play Video

Interesting publications

A clinically-compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis

Zhu L, et al., Valiente M

EMBO Molecular Medicine (2022)

The evolving landscape of brain metastasis

Valiente M, et al

Trends in Cancer. 4(3):176-196. (2018)

STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis

Priego N, et al., Valiente M

Nature Medicine 24(7):1024-1035 (2019)

A clinically-compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis

Zhu L, et al., Valiente M

EMBO Molecular Medicine (2022)

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

Monteiro C**, Miarka L**, et al., Valiente M

Nature Medicine (2022)

Machine learning identifies experimental brain metastasis subtypes based on their influence on neural circuits

Sanchez-Aguilera A**, Masmudi-Martín M**, et al., Valiente M

Cancer Cell (2023)

NEWS & EVENTS

Within the project, we aim to achieve significant scientific achievements for the treatment of this metastatic disease; however, no influence or effect will be achieved in the translation of these results, if we are not able to render and communicate the results. For this purpose, we will focus part of our efforts on making the project results visible to a wide audience.

Outreach

2024/11/10

El investigador que no quería ser científico y va a derribar la última frontera del cáncer

EL MUNDO

2024/02/05

Perspectivas matemáticas de las metástasis cerebrales PhD thesis

MOLAB

2024/01/30

Reunión conjunta: MOLAB y Unidad de Bioinformática del CNIO

MOLAB

2024/01/30

Análisis volumétrico: Replanteamiento de la evaluación de la respuesta de las metástasis cerebrales

Neuro-Oncology Advances

2024/01/17

Los criterios de respuesta para las metástasis cerebrales son revisados

Neuro-Oncology Advances

2023/12/28

Eva Ortega, directora científica del Biobanco del CNIO y directora de gestión de RENACER, nueva secretaria general de Investigación

CNIO noticias

2023/12/20

La actividad de MOLAB reconocida por la AECC, Asociación Española contra el Cáncer

AECC, Asociación Española contra el Cáncer

2023/12/13

Un biobanco "vivo" de muestras de metástasis cerebrales para la "medicina personalizada 2.0

Diagnostics world news

2023/11/07

El nuevo objetivo de la investigación oncológica es erradicar la metástasis antes de que aparezca

CNIO noticias

2023/10/30

La primera colección mundial de muestras vivas de metástasis cerebrales ayudará a aplicar la terapia más eficaz para cada paciente.

Trends in Cancer

2023/10/30

3ª Asamblea General "Red Nacional de Metástasis Cerebrales (RENACER): Tres años de trabajo conjunto"

Fundación Ramón Areces

2023/08/30

Un estudio revela que los tumores cerebrales "piratean" la comunicación entre neuronas

TELEMADRID

2023/07/23

La investigación del MOLAB desvela las leyes de crecimiento de las metástasis cerebrales

npj Systems Biology and Applications

2023/06/30

Comienza el mayor proyecto español para identificar genes que aumentan el riesgo de desarrollar cáncer

CNIO noticias

2023/06/26

Neurociencia del cáncer: cómo los tumores secuestran el sistema nervioso para crecer más rápido

EL PAÍS

2023/06/19

Un programa que busca los fármacos más eficaces para el cáncer de cada paciente ayuda a personalizar los tratamientos oncológicos

CNIO noticias

2023/05/05

RENACER, la primera colección de muestras vivas humanas de metástasis cerebral, premiada por el Grupo Español de Pacientes con Cáncer

CNIO

2023/04/30

MOLAB publica un conjunto de datos sobre metástasis cerebrales de acceso abierto

Scientific Data 10, 208 (2023)

2022/12/26

A través de la dinámica de crecimiento de las metástasis cerebrales se consigue diferenciar la necrosis por radiación de la recidiva

Neurooncology Advances

2022/10/05

2ª Asamblea general ''Red Nacional de Metástasis Cerebral (RENACER): Dos años de andadura conjunta''

2022/04/13

Investigadores españoles descubren cómo aumentar la eficacia de la radioterapia para la metástasis cerebral

ABC

2022/04/13

Investigadores españoles descubren cómo aumentar la eficacia de la radioterapia para la metástasis cerebral

La Vanguardia

2022/04/13

Investigadores españoles descubren cómo aumentar la eficacia de la radioterapia para la metástasis cerebral

El Mundo

2022/02/18

Investigadores diseñan una plataforma de cribado de fármacos compatible con biopsias de pacientes para combatir la metástasis

ABC

2021/01/26

RENACER, a national hospital network to boost research into brain metastases, is launched

CNIO

Un análisis de sangre y un fármaco mejoran la radioterapia contra metástasis cerebrales

How to make your research more translatable

In this video, Manuel Valiente, CNIO Brain Metastasis Group, discusses the challenges faced by basic scientists in translating their findings to clinical applications by sharing the example of the  @RENACERBrainMet network.

FUNDING